acute myeloid leukaemia

Categories:

SOP Numbers	Date of Commencement	Incorporated Material	Status
Balance of Probabilities	Date of Commencement	Incorporated Material	Status
72/2015	18/09/2017	Guide to Calculation of Cumulative Equivalent Dose ARPANSA 2 August 2017	Current	Compilation

SOP Numbers	Date of Commencement	Incorporated Material	Status
Reasonable Hypothesis	Date of Commencement	Incorporated Material	Status
71/2015	23/03/2020	Guide to Calculation of Cumulative Equivalent Dose ARPANSA 2 August 2017	Current	Compilation

Subject	Documents	Relevant SOPs	Date
RMA Declaration	Declaration acute myeloid leukaemia - decision not to amend BOP SOP - 11 March 2020 Statement of Reasons - decision not to amend BOP SOP - acute myeloid leukaemia - 28 February 2020	17/2020	11/03/2020
Reference List	Reference list - acute myeloid leukaemia - RMA meeting February 2020	71/2015 72/2015	11/02/2020
Amendment Explanatory Statements tabled in Houses of Parliament	Amendment SoP Explanatory Statement No. 17 of 2020 - RH - acute myeloid leukaemia - 23 March 2020	17/2020	23/03/2020
Amendment Explanatory Statements tabled in Houses of Parliament	Amendment Determination Explanatory Statement No 58 of 2017 Veterans Entitlements SOPs Cumulative Equivalent Dose 18 September 2017	58/2017 58/2017	18/09/2017
Explanatory Statements tabled in Houses of Parliament	SoP Explanatory statement 071 of 2015 RH 003 acute myeloid leukaemia 20 July 2015 SoP Explanatory statement 072 of 2015 BoP 003 acute myeloid leukaemia 20 July 2015	71/2015 72/2015	20/07/2015